Overview
- Several plaintiff firms are soliciting Erasca investors and moving for lead‑plaintiff status in a class action that covers January 14, 2025 to April 26, 2026 and remains uncertified.
- The lawsuits say Erasca misled the market by overstating ERAS‑0015’s preclinical advantage, hiding a patent and trade‑secret challenge from Revolution Medicines, and downplaying clinical safety concerns that later included a reported trial death.
- Plaintiff notices and complaints say corrective disclosures on April 27–28, 2026 — the Revolution Medicines letter and adverse Phase 1 data — triggered a steep share decline that erased billions in market value.
- The August 10, 2026 lead‑plaintiff deadline, set out in multiple firm notices, will determine who directs early discovery into the asserted IP dispute, the cross‑study preclinical comparisons, and the trial safety disclosures.
- If a lead plaintiff is appointed, discovery and possible SEC or whistleblower probes could reshape ERAS‑0015’s development path and will affect when and how investors may recover losses.